Skip to main content

Clinuvel Pharmaceuticals Ltd

corporate_fare Company Profile

Clinuvel Pharmaceuticals Ltd

CUVL·NASDAQ·Unknown·CIK 0001290877

Clinuvel Pharmaceuticals Ltd is a specialty pharmaceutical group headquartered in Melbourne, Australia, with global operations across Europe, Singapore and the U.S. It focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. As pioneers in photomedicine and the development of melanocortin technology, Clinuvel's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and repigmentation, all of whom currently lack therapeutic alternatives. The business objectives are to establish an integrated pharmaceutical company specializing in numerous melanocortin drugs, including various formulations and delivery methods. Clinuvel's lead therapy, SCENESSE, is approved for commercial distribution in Europe, the U.S., Israel, Canada and Australia as the world's first, and currently only, systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP, a rare metabolic disorder which causes severe anaphylactoid reactions to light and affects an estimated 5,000-10,000 individuals worldwide. By increasing the skin's eumelanin density and acting as an antioxidant, SCENESSE can help EPP patients reduce phototoxicity affecting the skin following exposure to sunlight and artificial UV light sources.

Clinuvel Pharmaceuticals Ltd (NASDAQ:CUVL) is a publicly traded company in the Unknown sector. Wiseek has independently scored 7 items for CUVL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for CUVL spans 6-K.

Recent high-impact activity:

  • Clinuvel Files NEURACTHEL® Instant Dossier With EU Regulators
  • Clinuvel Faces Board Spill Vote at Nov 6 AGM After 2025 Remuneration Strike
  • Clinuvel Posts 10th Straight Profit, Proposes Full Nasdaq Listing and ASX Delisting
  • Clinuvel Posts Tenth Straight Annual Profit, Cash Reserves Jump 12% to $252M
  • Clinuvel Sets December 2026 Readout for Vitiligo Drug, Plans Pivotal Trial

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$64.32M
Net Income
$23.18M
Diluted EPS
$0.46
Op. Cash Flow
$12.91M
Free Cash Flow
$11.85M
Gross Profit
$53.34M
Operating Income
$27.92M
Cash & Equivalents
$13.91M
Debt / Equity
0.00×
Net Margin
36.0%
Shares Outstanding
50.43M sh
Source: 20-F · filed 2026-10-30 · accession 0001493152-26-049364

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 1,942 shares in CUVL as of the October 30, 2026 settlement, a 87.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 33.7% of CUVL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,942 shares as of October 30, 2026
Change vs prior period▼ 87.6%
Days to cover1.00 at avg daily volume of 6,427
Daily short volume (FINRA facilities)33.7% of 5,073 shares on November 20, 2026
5-day average short volume29.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

CUVL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with C →
$4.71
52-week range · as of 2026-10-30 $4.71 – $8.92
Market cap
$240.3M
Volume
6.1K (1.0× avg)
3-mo avg 5.9K
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CUVL - Latest Insights

CUVL
Oct 30, 2026, 6:08 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.97
Real-time Price: $4.71 info
Change: -$0.260 (-5%) info
Market Cap: $240.303M info
CUVL
Oct 02, 2026, 11:28 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.03
Real-time Price: $4.71 info
Change: -$1.32 (-22%) info
Market Cap: $240.303M info
CUVL
Aug 27, 2026, 11:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.80
Real-time Price: $4.71 info
Change: -$2.09 (-31%) info
Market Cap: $240.303M info
CUVL
Aug 27, 2026, 1:42 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.62
Real-time Price: $4.71 info
Change: -$2.91 (-38%) info
Market Cap: $240.303M info
CUVL
Jul 28, 2026, 6:06 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.71 info
Change: -$2.29 (-33%) info
Market Cap: $240.303M info
CUVL
Jul 23, 2026, 12:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $4.71 info
Change: -$2.29 (-33%) info
Market Cap: $240.303M info
CUVL
Jul 21, 2026, 9:27 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.02
Real-time Price: $4.71 info
Change: -$2.31 (-33%) info
Market Cap: $240.303M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets